%0 Journal Article
%A Tix, Tobias
%A Alhomoud, Mohammad
%A Shouval, Roni
%A Iacoboni, Gloria
%A Scheffer Cliff, Edward R
%A Hansen, Doris K
%A Usmani, Saad Z
%A Salles, Gilles
%A Perales, Miguel-Angel
%A Cordas Dos Santos, David M
%A Rejeski, Kai
%T Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.
%J Molecular therapy
%V 33
%N 7
%@ 1525-0016
%C Amsterdam
%I Elsevier
%M DKFZ-2025-00681
%P 3163-3176
%D 2025
%Z Volume 33, Issue 7, 2 July 2025, Pages 3163-3176
%X Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and meta-analysis examined non-relapse mortality (NRM) with BsAb therapy in B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). A PubMed and Embase search up to October 2024 identified 29 studies (21 NHL, 8 MM) involving 2,535 patients. The overall NRM point estimate was 4.7
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40170355
%R 10.1016/j.ymthe.2025.03.048
%U https://inrepo02.dkfz.de/record/300219